Workflow
Biopharma Laboratory Services
icon
Search documents
What Analyst Projections for Key Metrics Reveal About Labcorp (LH) Q2 Earnings
ZACKS· 2025-07-21 14:21
Core Viewpoint - Labcorp Holdings (LH) is expected to report quarterly earnings of $4.14 per share, reflecting a 5.1% increase year-over-year, with revenues projected at $3.49 billion, an 8.3% increase from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Biopharma Laboratory Services' at $743.20 million, a 5.1% increase from the prior-year quarter [5]. - The average estimate for 'Revenues- Diagnostics Laboratories' is $2.74 billion, reflecting an 8.7% increase year-over-year [5]. Operating Income Estimates - 'Adjusted Operating Income- Biopharma Laboratory Services' is projected to reach $117.62 million, up from $107.40 million in the same quarter last year [6]. - 'Adjusted Operating Income- Diagnostics Laboratories' is expected to be $466.41 million, compared to $441.50 million a year ago [6]. Stock Performance - Labcorp shares have returned -6.9% over the past month, contrasting with the Zacks S&P 500 composite's +5.4% change [6]. - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6].
Labcorp (LH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-04-29 14:35
Core Insights - Labcorp reported revenue of $3.35 billion for the quarter ended March 2025, reflecting a year-over-year increase of 5.3% [1] - The company's EPS was $3.84, up from $3.68 in the same quarter last year, exceeding the consensus estimate of $3.73 by 2.95% [1] - The revenue fell short of the Zacks Consensus Estimate of $3.41 billion, resulting in a surprise of -2.04% [1] Financial Performance Metrics - The net book-to-bill ratio was reported at 1.1%, surpassing the estimated 1% by analysts [4] - Revenue from Biopharma Laboratory Services was $721.30 million, below the average estimate of $742.69 million, but showing a year-over-year increase of 1.5% [4] - Revenue from Diagnostics Laboratories was $2.63 billion, compared to the average estimate of $2.69 billion, with a year-over-year increase of 6.1% [4] - Adjusted Operating Income for Biopharma Laboratory Services was $106.90 million, slightly below the estimated $108.86 million [4] - Adjusted Operating Income for Diagnostics Laboratories was $427.50 million, compared to the average estimate of $435.69 million [4] Stock Performance - Labcorp's shares have returned -1.4% over the past month, while the Zacks S&P 500 composite has changed by -0.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]